Investor Overview

2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.

Read More >

Latest News

Neovasc Announces US $12.6 Million Registered Direct Offering Priced At-The-Market

> read full release

Archive >

Presentations and Events

Second Quarter 2020 Earnings Call, August 6, 4:30p.m ET


replay >

REDUCER - I interim results presented by
Pr. Verheye at PCR e-course 2020


view here >

Neovasc Presentation - June 2020


.pptx format (excel) > .pdf format (acrobat) >

Q2 earnings call

Recording from August 6, 2020  4:30p.m. ET

Financial Report Archives

2020 Financial Reports

News Release Archives

2020 News Releases

Share Information

Auditor
Grant Thornton LLP, Vancouver, BC

Legal Counsel
Blakes LLP, Vancouver, BC

Transfer Agent
Computershare, Vancouver, BC

Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com

To automatically receive news updates

register now